Shire to buy NPS Pharmaceuticals for $5.2bn

  • British pharmaceutical firm Shire is buying American biotech firm NPS Pharmaceuticals in a $5.2 billion deal, according to media reports.

    The deal would boost Shire’s place in the promising field of medicines meant for rare diseases, the UK company said.

    The boards of both companies have approved the agreement.

    Flemming Ornskov, the chief executive of Shire, described the acquisition of NPS Pharmaceuticals as “a significant step in advancing Shire's strategy to become a leading biotechnology company.”

    View List of Top Pharmaceutical Industries


    Tagged as: British pharmaceutical, Shire, NPS Pharmaceuticals, Flemming Ornskov, biotechnology, rare disease, business news